Marinus Pharmaceuticals Said On August 17, The PTAB Granted Co's Petition Seeking Post-grant Review Of Ovid Therapeutics' U.S. Patent No. 11,395,817
Portfolio Pulse from Charles Gross
Marinus Pharmaceuticals has been granted a post-grant review of Ovid Therapeutics' U.S. Patent No. 11,395,817 by the PTAB on August 17.
August 21, 2023 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Marinus Pharmaceuticals has been granted a post-grant review of a patent owned by Ovid Therapeutics, which could potentially impact their competitive position.
The granting of a post-grant review of a competitor's patent could potentially give Marinus Pharmaceuticals an advantage in the market, depending on the outcome of the review. This could lead to a positive impact on the company's stock in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100
NEGATIVE IMPACT
Ovid Therapeutics' U.S. Patent No. 11,395,817 is under post-grant review by the PTAB, initiated by Marinus Pharmaceuticals. This could potentially impact Ovid's competitive position.
The post-grant review of Ovid Therapeutics' patent could potentially lead to changes in the patent's validity or scope, which could impact the company's competitive position and potentially negatively affect its stock in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100